1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Issue 6 (June 2022) Authors: Gastaldelli, Amalia; Cusi, Kenneth; Fernández Landó, Laura; Bray, Ross; Brouwers, Bram; Rodríguez, Ángel Journal: Lancet Issue: Volume 10:Issue 6(2022) Page Start: 393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Issue 6 (11th February 2020) Authors: Frias, Juan Pablo; Nauck, Michael A.; Van, Joanna; Benson, Charles; Bray, Ross; Cui, Xuewei; Milicevic, Zvonko; Urva, Shweta; Haupt, Axel; Robins, Deborah A. Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 6(2020) Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Issue 6 (June 2022) Authors: Battelino, Tadej; Bergenstal, Richard M; Rodríguez, Angel; Fernández Landó, Laura; Bray, Ross; Tong, Zhentao; Brown, Katelyn Journal: Lancet Issue: Volume 10:Issue 6(2022) Page Start: 407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficient Estimation of the Efficacy and Safety Endpoints for Clinical Trials with Preplanned Dose Titrations. (2nd January 2023) Authors: Qu, Yongming; Cui, Xuewei; Bray, Ross; Sun, Nicholas Journal: Statistics in biopharmaceutical research Issue: Volume 15:Number 1(2023) Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Issue 10300 (14th August 2021) Authors: Ludvik, Bernhard; Giorgino, Francesco; Jódar, Esteban; Frias, Juan P; Fernández Landó, Laura; Brown, Katelyn; Bray, Ross; Rodríguez, Ángel Journal: Lancet Issue: Volume 398:Issue 10300(2021) Page Start: 583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗